Moderna, Merck unveil mRNA-based cancer vaccine that cuts spread

Moderna and Merck have announced promising results from a late-stage trial of their personalized mRNA cancer vaccine, Intisomeran. The vaccine, developed in conjunction with Merck's immunotherapy drug Keytruda, demonstrated a reduction in melanoma recurrence and tumor spread. This success in a new area of cancer treatment has led to a significant increase in Moderna's stock value. The experimental vaccine works by training the patient's immune system to target mutations in cancer cells, and similar approaches are being explored for other cancer types. If approved by regulators, Intisomeran could potentially benefit thousands of patients who have undergone surgery for high-risk melanoma tumors.

Merck and Moderna have announced encouraging results from a clinical trial of their experimental melanoma vaccine, intismeran autogene. The companies stated that when used in combination with Merck's Keytruda treatment, the vaccine demonstrated statistically significant and clinically meaningful improvements for skin cancer patients. This therapeutic vaccine, unlike conventional ones, aims to treat existing diseases by stimulating the body's immune system against tumors. These positive trial outcomes suggest a potential pathway toward regulatory approval for the treatment.

Moderna's shares surged over 120% after the company announced positive initial results for its experimental mRNA cancer treatment, intisomeran. Developed in partnership with Merck, the treatment is an mRNA-based vaccine designed to target individual tumor mutations. In a study involving melanoma patients, intisomeran was administered alongside Merck's immunotherapy drug, Keytruda, and compared to Keytruda alone. Preliminary findings indicate that patients receiving the combination treatment experienced longer periods without cancer recurrence or metastasis compared to those treated with Keytruda solely. The companies plan to present these study results at an upcoming medical meeting. Merck's shares also saw an increase of approximately 11%.